Want to see RGEN full AI Analyst Report?
Top Page
Repligen
(NASDAQ:RGEN)
Select Model
Select Model
Rating:69Neutral
Price Target:
$179.00
▲(35.65% Upside)
Action:Reiterated
Date:07/29/26
The score is driven primarily by improving financial performance (earnings recovery, strong cash flow, and manageable leverage) and a supportive earnings update (growth, margin expansion, and raised EPS guidance). These positives are tempered by a very demanding valuation (high P/E with no dividend support) and only moderately confirmed technical strength due to missing momentum indicators. The BioLife acquisition adds strategic upside but introduces execution/integration risk.
Positive Factors
Strong cash generation
Consistent, growing operating and free cash flow provides durable financial flexibility. It funds R&D, modest CapEx (~3–4% of revenue), M&A and working capital without immediate financing, supports margins through investment, and cushions the business versus cyclical revenue swings over the next 2–6 months and beyond.
Negative Factors
Revenue and margin volatility
Historic swings in revenue and margins undermine predictability for capital planning and margin sustainability. Volatility heightens execution risk for margin improvements and makes it harder to rely on short‑term gains as durable, complicating forecasting and potentially pressuring reinvestment decisions over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Consistent, growing operating and free cash flow provides durable financial flexibility. It funds R&D, modest CapEx (~3–4% of revenue), M&A and working capital without immediate financing, supports margins through investment, and cushions the business versus cyclical revenue swings over the next 2–6 months and beyond.
Read all positive factors
Repligen (RGEN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.25B
Dividend YieldN/A
Average Volume (3M)1.14M
Price to Earnings (P/E)221.5
Beta (1Y)1.21
Revenue Growth16.49%
EPS GrowthN/A
CountryUS
Employees2,000
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.74
Shares Outstanding56,435,620
10 Day Avg. Volume1,377,252
30 Day Avg. Volume1,139,495
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.38
Price to Sales (P/S)12.48
P/FCF Ratio98.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$172.45Price Target Upside30.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)2.06
Revenue Forecast (FY)$827.38M
Repligen Business Overview & Revenue Model
Company Description
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Euro...
How the Company Makes Money
Repligen makes money primarily by selling bioprocessing products used during the development and commercial manufacturing of biologic drugs. Its revenue model is largely product-based and is typically driven by (1) recurring consumables tied to cu...
Repligen Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 03, 2026
Earnings Call Sentiment Positive
The call was predominantly positive: the company reported healthy top-line growth ($194M, +15% reported, +11% organic), notable margin expansion (gross margin +180 bps, operating margin +160 bps), strong franchise performances (Analytics +50%+, Chromatography >25%, Proteins mid-teens), solid cash position ($785M), and raised adjusted EPS guidance. Management launched a transformation office targeting at least 1 point of annualized margin benefit by end of 2027 and announced a strategic OEM partnership in China. Key headwinds are mostly timing and structural: divestiture of a loss-making Polymem reduced revenue (~$7M), ATF/gene therapy customer timing moderated near-term growth (expected to rebound in 2027), some Q1 margin benefits may normalize, and there is execution risk around customer readiness for capital equipment and competition in China. Overall, positives (growth, margins, guidance, strategic initiatives, cash) materially outweigh the manageable lowlights tied to timing, one-off costs, and a small divestiture impact.Positive Updates
Strong Q1 Revenue and Organic Growth
Reported revenue of $194M in Q1, up 15% year-over-year; 11% organic growth excluding acquisitions and FX; FX contributed ~3 percentage points and two months of inorganic revenue from an upstream Analytics acquisition.
Negative Updates
Polymem Divestiture Reduced Revenue
Sale of noncore Polymem business (France) removed approximately $7M of full-year revenue and reflected a prior adjusted operating loss; divestiture improves margin profile but lowers reported revenue guidance by ~$7M.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Q1 Revenue and Organic Growth
Reported revenue of $194M in Q1, up 15% year-over-year; 11% organic growth excluding acquisitions and FX; FX contributed ~3 percentage points and two months of inorganic revenue from an upstream Analytics acquisition.
Read all positive updates
Company Guidance
Repligen reiterated full‑year 2026 guidance of $803–$833M of revenue (9%–13% reported and organic growth), reflecting the Polymem divestiture (≈$7M revenue removal) and just under a 1‑point FX benefit; segment assumptions are mid‑single‑digit Filtration, >20% Chromatography, proteins > low‑double‑digits, and Analytics >20%. They expect 110–160 bps of gross‑margin expansion, $124–$132M of adjusted operating income (160–200 bps operating‑margin expansion, ~30 bps higher at the midpoint versus prior guide), $90M of adjusted other income, a 22–23% adjusted tax rate, and adjusted diluted EPS of $1.97–$2.05 (up $0.26–$0.34 y/y and $0.04 above prior guide). Management said Q2 organic growth should be similar to Q1, Q2 gross margin will be slightly below the full‑year range (Q3 likely the lowest‑margin quarter), CapEx of ~3–4% of revenue, a couple million dollars of tariff surcharges, $5–$6M of excluded one‑time transformation charges through 2027, and at least a 1‑point annualized margin benefit from the transformation office by end‑2027.Repligen Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
74
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 785.10M | 738.26M | 634.44M | 632.36M | 801.54M | 670.53M |
| Gross Profit | 400.80M | 347.62M | 274.64M | 278.44M | 455.71M | 391.25M |
| EBITDA | 121.83M | 164.30M | 80.26M | 145.32M | 277.31M | 203.27M |
| Net Income | 41.54M | 48.89M | -25.51M | 35.60M | 185.96M | 128.29M |
Balance Sheet | ||||||
| Total Assets | 2.95B | 2.95B | 2.83B | 2.83B | 2.53B | 2.36B |
| Cash, Cash Equivalents and Short-Term Investments | 810.45M | 767.63M | 757.36M | 751.32M | 623.76M | 603.81M |
| Total Debt | 690.94M | 689.95M | 686.25M | 711.80M | 422.96M | 366.05M |
| Total Liabilities | 838.15M | 843.57M | 856.95M | 866.34M | 620.90M | 608.29M |
| Stockholders Equity | 2.11B | 2.11B | 1.97B | 1.96B | 1.91B | 1.75B |
Cash Flow | ||||||
| Free Cash Flow | 110.78M | 93.90M | 142.49M | 74.93M | 38.74M | 51.93M |
| Operating Cash Flow | 134.86M | 117.42M | 175.39M | 113.92M | 172.08M | 119.02M |
| Investing Cash Flow | -222.60M | -298.47M | -86.38M | -123.28M | -233.24M | -221.17M |
| Financing Cash Flow | -11.79M | -15.21M | -82.90M | 248.96M | -13.34M | 961.00K |
Repligen Technical Analysis
Positive
131.96
Price Trends
137.88
Positive
127.84
Positive
139.86
Positive
Market Momentum
5.31
Negative
69.37
Neutral
95.27
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Positive. The current price of 131.96 is below the 20-day moving average (MA) of 145.45, below the 50-day MA of 137.88, and below the 200-day MA of 139.86, indicating a bullish trend. The MACD of 5.31 indicates Negative momentum. The RSI at 69.37 is Neutral, neither overbought nor oversold. The STOCH value of 95.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RGEN.
Repligen Risk Analysis
Repligen disclosed 16 risk factors in its most recent earnings report. Repligen reported the most risks in the "Macro & Political" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Repligen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $5.32B | 36.34 | 9.07% | ― | 10.51% | 20.67% | |
69 Neutral | $9.25B | 221.49 | 1.98% | ― | 16.49% | ― | |
69 Neutral | $8.61B | 24.18 | 13.52% | 1.43% | 8.93% | -5.14% | |
68 Neutral | $5.53B | 36.54 | 9.63% | 0.32% | 14.73% | 7.43% | |
63 Neutral | $5.99B | -35.09 | -2.67% | ― | 8.85% | 37.70% | |
59 Neutral | $5.72B | -5.80 | -31.83% | 1.03% | -14.49% | -644.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
RGEN
Repligen
163.90
52.02
46.50%
ATR
AptarGroup
135.42
-2.36
-1.72%
MMSI
Merit Medical Systems
89.04
5.00
5.95%
TFX
Teleflex
134.98
20.34
17.75%
STVN
Stevanato Group
20.27
-1.50
-6.89%
BLCO
Bausch + Lomb Corporation
16.78
3.15
23.11%
Repligen Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Repligen to Acquire BioLife, Expanding Cell Therapy Reach
Positive
Jul 22, 2026
On July 21, 2026, Repligen agreed to acquire BioLife Solutions in a cash-and-stock merger valuing BioLife at about $1.5 billion, or $31.00 per share, with directors of both companies unanimously approving the deal. The transaction will proceed via...
Executive/Board ChangesShareholder Meetings
Repligen Shareholders Approve Directors, Auditor and Pay Plan
Positive
May 15, 2026
On May 14, 2026, Repligen Corporation held its 2026 Annual Meeting of Stockholders, with 54,022,359 of 56,399,274 eligible shares represented, constituting a quorum. Shareholders were asked to elect nine directors, ratify Ernst Young LLP as indep...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.